Skip to main content
Livermore
Livermore
US stocksTW
ZHEN

Takeda Pharmaceutical Co Ltd

TKPHF
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001395064

In the last 90 days, Takeda Pharmaceutical Co Ltd insiders filed 0 open-market purchases and 6 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Other share classesTAK

Currency
JPY
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 14, 2026, 1:13 AM ET

Amounts are in JPY, the currency Takeda Pharmaceutical Co Ltd reports in. Lines marked ≈ US$ convert key figures to US dollars.

Revenue flow, FY2025

Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Income statement

Each column is one fiscal year, newest first.

Income statement of Takeda Pharmaceutical Co Ltd, annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endMar 31, 2025Mar 31, 2024Mar 31, 2023Mar 31, 2022Mar 31, 2021
Filing20-F20-F20-F20-F20-F
Reported–––––
RevenueJPY 4.58T≈ US$30.1BJPY 4.26T≈ US$29.5BJPY 4.03T≈ US$29.8BJPY 3.57T≈ US$31.8BJPY 3.20T≈ US$30.1B
Cost of revenueJPY 1.58TJPY 1.43TJPY 1.24TJPY 1.11TJPY 994.3B
Research and developmentJPY 730.2BJPY 729.9BJPY 633.3BJPY 526.1BJPY 455.8B
Selling, general and administrativeJPY 1.10TJPY 1.05TJPY 997.3BJPY 886.4BJPY 875.7B
Operating incomeJPY 342.6BJPY 214.1BJPY 490.5BJPY 460.8BJPY 509.3B
Interest expenseJPY 210.1BJPY 219.8BJPY 169.7BJPY 166.6BJPY 248.6B
Income taxJPY 66.9BJPY -91.4BJPY 58.1BJPY 72.4BJPY -9.94B
Net incomeJPY 108.1B≈ US$710.3MJPY 144.2B≈ US$999.2MJPY 317.0B≈ US$2.35BJPY 230.2B≈ US$2.05BJPY 376.2B≈ US$3.55B
EPS, basicJPY 68.36JPY 92.09JPY 204.29JPY 147.14JPY 240.72
EPS, dilutedJPY 67.23JPY 91.16JPY 201.94JPY 145.87JPY 238.96
Weighted shares, basic1.58B1.56B1.55B1.56B1.56B
Weighted shares, diluted1.61B1.58B1.57B1.58B1.57B
Margins and growth
Operating margin7.5%5.0%12.2%12.9%15.9%
Net margin2.4%3.4%7.9%6.4%11.8%
Revenue growth, year over year+7.5%+5.9%+12.8%+11.6%−2.8%
Net income growth, year over year−25.0%−54.5%+37.7%−38.8%+749.3%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Takeda Pharmaceutical Co Ltd, annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endMar 31, 2025Mar 31, 2024Mar 31, 2023Mar 31, 2022Mar 31, 2021
Filing20-F20-F20-F20-F20-F
Reported–––––
Cash and equivalentsJPY 385.1BJPY 457.8BJPY 533.5BJPY 849.7BJPY 966.2B
Accounts receivableJPY 770.9BJPY 718.7BJPY 674.7BJPY 710.3BJPY 788.3B
InventoryJPY 1.22TJPY 1.21TJPY 986.5BJPY 853.2BJPY 753.9B
Total current assetsJPY 2.52TJPY 2.56TJPY 2.40TJPY 2.59TJPY 2.71T
Property, plant and equipment––JPY 1.69TJPY 1.58TJPY 1.45T
GoodwillJPY 5.32TJPY 5.41TJPY 4.79TJPY 4.41TJPY 4.03T
Intangible assetsJPY 3.63TJPY 4.27TJPY 4.27TJPY 3.82TJPY 3.91T
Total assetsJPY 14.2T≈ US$95.1BJPY 15.1T≈ US$99.9BJPY 14.0T≈ US$105.1BJPY 13.2T≈ US$108.5BJPY 12.9T≈ US$116.7B
Accounts payableJPY 475.5BJPY 547.5BJPY 649.2BJPY 516.3BJPY 343.8B
Total current liabilitiesJPY 2.51TJPY 2.31TJPY 2.48TJPY 2.15TJPY 1.77T
Long-term debtJPY 3.97TJPY 4.48TJPY 4.04TJPY 4.14TJPY 4.61T
Total liabilitiesJPY 7.31TJPY 7.83TJPY 7.60TJPY 7.49TJPY 7.74T
Shareholders' equityJPY 6.94TJPY 7.27TJPY 6.35TJPY 5.68TJPY 5.18T

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Takeda Pharmaceutical Co Ltd, annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endMar 31, 2025Mar 31, 2024Mar 31, 2023Mar 31, 2022Mar 31, 2021
Filing20-F20-F20-F20-F20-F
Reported–––––
Operating cash flowJPY 1.06T≈ US$6.94BJPY 716.3B≈ US$4.96BJPY 977.2B≈ US$7.23BJPY 1.12T≈ US$10.0BJPY 1.01T≈ US$9.53B
Capital expendituresJPY 200.8BJPY 175.4BJPY 140.7BJPY 123.3BJPY 111.2B
Free cash flowJPY 856.4B≈ US$5.62BJPY 540.9B≈ US$3.75BJPY 836.5B≈ US$6.19BJPY 999.9B≈ US$8.91BJPY 899.7B≈ US$8.48B
Depreciation and amortizationJPY 761.4BJPY 728.0BJPY 664.4BJPY 583.2BJPY 559.7B
Dividends paidJPY 302.5BJPY 287.2BJPY 279.4BJPY 283.7BJPY 283.4B
Share buybacksJPY 51.9BJPY 2.33BJPY 26.9BJPY 77.5BJPY 2.14B
Investing cash flowJPY -367.1BJPY -463.9BJPY -607.1BJPY -198.1BJPY 393.5B
Financing cash flowJPY -751.4BJPY -354.4BJPY -709.1BJPY -1.07TJPY -1.09T

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Takeda Pharmaceutical Co Ltd by cover date
Cover dateShares outstandingChange in a yearFiling
Mar 31, 20201.56B−0.5%SEC
Mar 31, 20191.57B–SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
  • ≈ US$ figures convert JPY at FRED H.10 exchange rates (Federal Reserve): the average rate over the period for income and cash flow, and the rate on the period-end date, or the last business day before it, for the balance sheet.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.